Theratechnologies Inc. (NASDAQ:THTX) has earned a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Theratechnologies’ rating score has improved by 28.3% from 90 days ago as a result of various analysts’ ratings changes.
Brokerages have set a 12-month consensus price target of $6.43 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given Theratechnologies an industry rank of 72 out of 255 based on the ratings given to related companies.
A number of brokerages have commented on THTX. Canaccord Genuity began coverage on shares of Theratechnologies in a research note on Monday, December 2nd. They issued a “buy” rating on the stock. ValuEngine upgraded shares of Theratechnologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Zacks Investment Research downgraded shares of Theratechnologies from a “hold” rating to a “sell” rating in a research note on Friday, January 10th. Finally, Mackie upgraded shares of Theratechnologies from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th.
Theratechnologies stock opened at $2.79 on Wednesday. The company has a debt-to-equity ratio of 1.68, a quick ratio of 2.04 and a current ratio of 2.51. The stock has a 50-day moving average price of $2.87. Theratechnologies has a 1-year low of $2.60 and a 1-year high of $7.14.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Further Reading: How Investors Can Profit from Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.